We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+50.68%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$548M
AUM Growth
+$192M
Cap. Flow
+$43.1M
Cap. Flow %
7.87%
Top 10 Hldgs %
43.03%
Holding
102
New
19
Increased
25
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$28M
2
LIAN
LianBio American Depositary Shares
LIAN
+$10.7M
3
NUVL
Nuvalent
NUVL
+$7.74M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.35M
5
ALKS icon
Alkermes
ALKS
+$6.66M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$10.2M
2
KURA icon
Kura Oncology
KURA
+$6.54M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.41M
4
PRTA icon
Prothena Corp
PRTA
+$3.82M
5
KRYS icon
Krystal Biotech
KRYS
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
51
DELISTED
Mersana Therapeutics
MRSN
$2.32M 0.42%
40,000
-74,000
-65% -$2.98M
IMTX icon
52
Immatics
IMTX
$1.26B
$2.11M 0.38%
200,000
– –
PEN icon
53
Penumbra
PEN
$12.5B
$1.89M 0.34%
+7,500
New +$1.66M
TRML
54
DELISTED
Tourmaline Bio
TRML
$1.78M 0.33%
68,081
+28,081
+70% +$562K
ADCT icon
55
ADC Therapeutics
ADCT
$160M
$1.68M 0.31%
1,013,540
-86,460
-8% -$79.8K
PCVX icon
56
Vaxcyte
PCVX
$8.01B
$1.57M 0.29%
25,000
– –
KALV
57
DELISTED
KalVista Pharmaceuticals
KALV
$1.54M 0.28%
125,969
-152,323
-55% -$1.39M
APLS
58
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$1.5M 0.27%
+25,000
New +$1.27M
MIRM icon
59
Mirum Pharmaceuticals
MIRM
$7.11B
$1.48M 0.27%
50,000
+20,000
+67% +$605K
NAMS icon
60
NewAmsterdam Pharma
NAMS
$3.47B
$1.4M 0.26%
125,000
– –
NBIX icon
61
Neurocrine Biosciences
NBIX
$17.4B
$1.32M 0.24%
+10,000
New +$1.15M
NARI
62
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.3M 0.24%
+20,000
New +$1.2M
ALLO icon
63
Allogene Therapeutics
ALLO
$611M
$1.28M 0.23%
+400,000
New +$1.13M
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.23M 0.23%
42,670
-227,330
-84% -$5.41M
VRDN icon
65
Viridian Therapeutics
VRDN
$2.05B
$1.09M 0.2%
+50,000
New +$789K
BHVN icon
66
Biohaven
BHVN
$2.24B
$893K 0.16%
20,866
-9,290
-31% -$289K
PBYI icon
67
Puma Biotechnology
PBYI
$422M
$876K 0.16%
202,349
– –
FULC icon
68
Fulcrum Therapeutics
FULC
$241M
$844K 0.15%
+125,000
New +$555K
ALKS icon
69
PUT
Alkermes
ALKS
$8.62B
$749K 0.14%
+27,000
New +$701K
TECX
70
Tectonic Therapeutic
TECX
$605M
$680K 0.12%
41,667
– –
IMTXW
71
DELISTED
Immatics N.V. Warrants
IMTXW
$547K 0.1%
187,204
– –
NAMSW icon
72
NewAmsterdam Pharma Warrant
NAMSW
$83.7M
$429K 0.08%
137,000
– –
TERN
73
DELISTED
Terns Pharmaceuticals
TERN
$428K 0.08%
66,000
-259,000
-80% -$1.37M
NUVB icon
74
Nuvation Bio
NUVB
$2.18B
$378K 0.07%
250,000
– –
CNTX icon
75
Context Therapeutics
CNTX
$56.6M
$372K 0.07%
328,817
– –
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Affinity Asset Advisors held 102 positions worth $548M, up 54% from $356M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $43.1M of net new capital in Q4 2023, opening 19 new positions and adding to 25 existing holdings. Its largest new stake was Immunogen Inc: 1,404,608 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Apogee Therapeutics, an estimated $10.2M trimmed.

  • Affinity Asset Advisors's largest Q4 2023 buy was Immunogen Inc: 1,404,608 shares worth $41.6M.
  • Affinity Asset Advisors added most to LianBio American Depositary Shares in Q4 2023, an estimated $10.7M increase.
  • Affinity Asset Advisors's biggest Q4 2023 reduction was Apogee Therapeutics, cutting an estimated $10.2M.
  • Affinity Asset Advisors fully exited Prothena Corp in Q4 2023, selling an estimated $3.82M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $548M portfolio in Q4 2023.
  • Affinity Asset Advisors opened 19 new positions and closed 20 in Q4 2023.
  • Affinity Asset Advisors's portfolio value rose 54% quarter-over-quarter to $548M.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.